Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OSE Immunotherapeutics SA

ose-immuno.com/en

Latest From OSE Immunotherapeutics SA

Tech Transfer Roundup: Tmunity Targets Pediatric Glioma With UCSF-Discovered TCR Therapy

Bayer will collaborate with start-up Hope Medicine to develop antibody therapies targeting the PRL receptor. WARF and Sanford Burnham Prebys partner on translational research.

Research & Development Deals

BI’s Business Development Focus Remains On Early Collaboration

Boehringer Ingelheim’s US business development head Ioannis Sapountzis outlines BI’s efforts to catch up with competitors in NASH and immuno-oncology via early-stage partnerships and licensing deals.

Business Strategies Research and Development Strategies

Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns

Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
Business Strategies Deals

OSE Immunotherapeutics Adds Boehringer Ingelheim To Its Pharma Partnering List

Collaborating with the German family-controlled drug maker on OSE's novel checkpoint inhibitor aligns with French firm's strategy of partnering its portfolio candidates.

Analysis Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • OSE Pharma SA
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • OSE Immunotherapeutics SA
  • Senior Management
  • Alexis Peyroles, CEO
    Bernard Vanhove, COO, R&D and Intl Scientific Collaborations
  • Contact Info
  • OSE Immunotherapeutics SA
    Phone: 2 28 29 10 10
    22, boulevard Benoni Goullin
    Nantes, 44200
    France
Advertisement
Advertisement
UsernamePublicRestriction

Register